A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Healthy Person Clinical Trial

Official title: A Randomized, Double-blind, Placebo-controlled, Dose-escalating, Single-dose, Oral Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of Flunotinib Maleate Tablets in Healthy Adult Subjects in China.

Status Recruiting

Clinical Trial Summary

Evaluate the safety and tolerability of a single increasing dose of Flibanserin Maleate tablets administered orally to healthy adult Chinese subjects; preliminarily assess the pharmacokinetic characteristics of a single dose of oral Flibanserin Maleate tablets

Clinical Trial Description

The goal of this clinical trial is to evaluate the safety of sflunotinib maleate tablets. The main question[s] it aims to answer are:

1. The safety and tolerability of single oral doses of flunotinib maleate tablets in escalating doses in healthy adult subjects in China

2. The pharmacokinetic characteristics of a single dose of oral flunotinib maleate tablets Participants will divide into experimental group and placebo group, conduct single oral administration safety and tolerability test group by group ;

Related Conditions & MeSH terms

• Healthy Person

• NCT number: NCT06387966
• Study type: Interventional
• Source: Chengdu Zenitar Biomedical Technology Co., Ltd
• Contact: Liangkun Sun, bachelor
• Phone: 15885742617
• Email: liangkunsun@zenitar.cn
• Status: Recruiting
• Phase: Phase 1
• Start date: February 29, 2024
• Completion date: December 30, 2024